Does the media refer more to TLSI or DRTS?

In the previous week, Alpha Tau Medical had 4 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 6 mentions for Alpha Tau Medical and 2 mentions for TriSalus Life Sciences. TriSalus Life Sciences' average media sentiment score of 1.01 beat Alpha Tau Medical's score of 0.97 indicating that TriSalus Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TriSalus Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alpha Tau Medical 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TLSI or PRCT?

In the previous week, PROCEPT BioRobotics had 34 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 36 mentions for PROCEPT BioRobotics and 2 mentions for TriSalus Life Sciences. TriSalus Life Sciences' average media sentiment score of 1.01 beat PROCEPT BioRobotics' score of 0.29 indicating that TriSalus Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TriSalus Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PROCEPT BioRobotics 9 Very Positive mention(s) 0 Positive mention(s) 25 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor STAA or TLSI?

In the previous week, STAAR Surgical had 4 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 6 mentions for STAAR Surgical and 2 mentions for TriSalus Life Sciences. STAAR Surgical's average media sentiment score of 1.02 beat TriSalus Life Sciences' score of 1.01 indicating that STAAR Surgical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment STAAR Surgical 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TriSalus Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TLSI or BVS?

In the previous week, TriSalus Life Sciences and TriSalus Life Sciences both had 2 articles in the media. TriSalus Life Sciences' average media sentiment score of 1.01 beat Bioventus' score of 0.89 indicating that TriSalus Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TriSalus Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bioventus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer NNNN or TLSI?

TriSalus Life Sciences has a consensus target price of $7.50, suggesting a potential upside of 55.28%. Given TriSalus Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe TriSalus Life Sciences is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TriSalus Life Sciences 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has stronger valuation & earnings, NNNN or TLSI?

Anbio Biotechnology has higher earnings, but lower revenue than TriSalus Life Sciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 127.64 $6.40M N/A N/A TriSalus Life Sciences $45.15M 6.59 -$39.23M -$1.30 N/A

Is NNNN or TLSI more profitable?

Anbio Biotechnology has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -62.59%. Company Net Margins Return on Equity Return on Assets Anbio Biotechnology N/A N/A N/A TriSalus Life Sciences -62.59% N/A -64.47%

TriSalus Life Sciences (TLSI) Competitors

$4.83 -0.10 (-2.03%)

As of 08/28/2026 04:00 PM Eastern

Compare

TLSI vs. DRTS, PRCT, STAA, BVS, and NNNN

Should you buy TriSalus Life Sciences stock or one of its competitors? TriSalus Life Sciences's main competitors and comparable companies include Alpha Tau Medical (DRTS), PROCEPT BioRobotics (PRCT), STAAR Surgical (STAA), Bioventus (BVS), and Anbio Biotechnology (NNNN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does TriSalus Life Sciences compare to Alpha Tau Medical?

TriSalus Life Sciences (NASDAQ:TLSI) and Alpha Tau Medical (NASDAQ:DRTS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

Alpha Tau Medical has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -62.59%. TriSalus Life Sciences' return on equity of 0.00% beat Alpha Tau Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-62.59%	N/A	-64.47%
Alpha Tau Medical	N/A	-138.12%	-81.68%

TriSalus Life Sciences currently has a consensus target price of $7.50, indicating a potential upside of 55.28%. Alpha Tau Medical has a consensus target price of $12.80, indicating a potential downside of 12.57%. Given TriSalus Life Sciences' higher probable upside, research analysts clearly believe TriSalus Life Sciences is more favorable than Alpha Tau Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Alpha Tau Medical	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

TriSalus Life Sciences has higher revenue and earnings than Alpha Tau Medical. Alpha Tau Medical is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$45.15M	6.59	-$39.23M	-$1.30	N/A
Alpha Tau Medical	N/A	N/A	-$42.63M	-$1.04	N/A

In the previous week, Alpha Tau Medical had 4 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 6 mentions for Alpha Tau Medical and 2 mentions for TriSalus Life Sciences. TriSalus Life Sciences' average media sentiment score of 1.01 beat Alpha Tau Medical's score of 0.97 indicating that TriSalus Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TriSalus Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alpha Tau Medical	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

2.6% of TriSalus Life Sciences shares are owned by institutional investors. Comparatively, 2.7% of Alpha Tau Medical shares are owned by institutional investors. 16.3% of TriSalus Life Sciences shares are owned by insiders. Comparatively, 39.5% of Alpha Tau Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

TriSalus Life Sciences has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market. Comparatively, Alpha Tau Medical has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market.

Summary

Alpha Tau Medical beats TriSalus Life Sciences on 8 of the 15 factors compared between the two stocks.

How does TriSalus Life Sciences compare to PROCEPT BioRobotics?

TriSalus Life Sciences (NASDAQ:TLSI) and PROCEPT BioRobotics (NASDAQ:PRCT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

TriSalus Life Sciences has higher earnings, but lower revenue than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$45.15M	6.59	-$39.23M	-$1.30	N/A
PROCEPT BioRobotics	$308.05M	3.87	-$95.57M	-$1.94	N/A

PROCEPT BioRobotics has a net margin of -32.53% compared to TriSalus Life Sciences' net margin of -62.59%. TriSalus Life Sciences' return on equity of 0.00% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-62.59%	N/A	-64.47%
PROCEPT BioRobotics	-32.53%	-30.62%	-22.10%

In the previous week, PROCEPT BioRobotics had 34 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 36 mentions for PROCEPT BioRobotics and 2 mentions for TriSalus Life Sciences. TriSalus Life Sciences' average media sentiment score of 1.01 beat PROCEPT BioRobotics' score of 0.29 indicating that TriSalus Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TriSalus Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PROCEPT BioRobotics	9 Very Positive mention(s)	0 Positive mention(s)	25 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

TriSalus Life Sciences presently has a consensus target price of $7.50, suggesting a potential upside of 55.28%. PROCEPT BioRobotics has a consensus target price of $28.00, suggesting a potential upside of 34.42%. Given TriSalus Life Sciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe TriSalus Life Sciences is more favorable than PROCEPT BioRobotics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
PROCEPT BioRobotics	2 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.19

2.6% of TriSalus Life Sciences shares are owned by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 16.3% of TriSalus Life Sciences shares are owned by company insiders. Comparatively, 4.0% of PROCEPT BioRobotics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

TriSalus Life Sciences has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market. Comparatively, PROCEPT BioRobotics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market.

Summary

TriSalus Life Sciences beats PROCEPT BioRobotics on 9 of the 17 factors compared between the two stocks.

How does TriSalus Life Sciences compare to STAAR Surgical?

STAAR Surgical (NASDAQ:STAA) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

STAAR Surgical has a net margin of 1.13% compared to TriSalus Life Sciences' net margin of -62.59%. STAAR Surgical's return on equity of 9.05% beat TriSalus Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STAAR Surgical	1.13%	9.05%	6.99%
TriSalus Life Sciences	-62.59%	N/A	-64.47%

96.7% of STAAR Surgical shares are owned by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are owned by institutional investors. 39.9% of STAAR Surgical shares are owned by company insiders. Comparatively, 16.3% of TriSalus Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

STAAR Surgical has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, TriSalus Life Sciences has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market.

STAAR Surgical currently has a consensus target price of $28.40, suggesting a potential upside of 28.45%. TriSalus Life Sciences has a consensus target price of $7.50, suggesting a potential upside of 55.28%. Given TriSalus Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe TriSalus Life Sciences is more favorable than STAAR Surgical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STAAR Surgical	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.08
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

TriSalus Life Sciences has lower revenue, but higher earnings than STAAR Surgical. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STAAR Surgical	$339.59M	3.26	-$80.45M	$0.07	315.86
TriSalus Life Sciences	$45.15M	6.59	-$39.23M	-$1.30	N/A

In the previous week, STAAR Surgical had 4 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 6 mentions for STAAR Surgical and 2 mentions for TriSalus Life Sciences. STAAR Surgical's average media sentiment score of 1.02 beat TriSalus Life Sciences' score of 1.01 indicating that STAAR Surgical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STAAR Surgical	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TriSalus Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

STAAR Surgical beats TriSalus Life Sciences on 12 of the 16 factors compared between the two stocks.

How does TriSalus Life Sciences compare to Bioventus?

TriSalus Life Sciences (NASDAQ:TLSI) and Bioventus (NASDAQ:BVS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

TriSalus Life Sciences currently has a consensus target price of $7.50, suggesting a potential upside of 55.28%. Bioventus has a consensus target price of $16.80, suggesting a potential upside of 21.39%. Given TriSalus Life Sciences' higher possible upside, analysts plainly believe TriSalus Life Sciences is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Bioventus	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Bioventus has higher revenue and earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$45.15M	6.59	-$39.23M	-$1.30	N/A
Bioventus	$568.09M	2.05	$22.73M	$0.77	17.97

Bioventus has a net margin of 9.36% compared to TriSalus Life Sciences' net margin of -62.59%. Bioventus' return on equity of 28.08% beat TriSalus Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-62.59%	N/A	-64.47%
Bioventus	9.36%	28.08%	9.82%

2.6% of TriSalus Life Sciences shares are owned by institutional investors. Comparatively, 62.9% of Bioventus shares are owned by institutional investors. 16.3% of TriSalus Life Sciences shares are owned by company insiders. Comparatively, 33.5% of Bioventus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, TriSalus Life Sciences and TriSalus Life Sciences both had 2 articles in the media. TriSalus Life Sciences' average media sentiment score of 1.01 beat Bioventus' score of 0.89 indicating that TriSalus Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TriSalus Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bioventus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TriSalus Life Sciences has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market. Comparatively, Bioventus has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

Summary

Bioventus beats TriSalus Life Sciences on 12 of the 15 factors compared between the two stocks.

How does TriSalus Life Sciences compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

TriSalus Life Sciences has a consensus target price of $7.50, suggesting a potential upside of 55.28%. Given TriSalus Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe TriSalus Life Sciences is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Anbio Biotechnology has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -62.59%.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
TriSalus Life Sciences	-62.59%	N/A	-64.47%

In the previous week, Anbio Biotechnology and Anbio Biotechnology both had 2 articles in the media. Anbio Biotechnology's average media sentiment score of 1.44 beat TriSalus Life Sciences' score of 1.01 indicating that Anbio Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Anbio Biotechnology	Positive
TriSalus Life Sciences	Positive

2.6% of TriSalus Life Sciences shares are held by institutional investors. 16.3% of TriSalus Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Anbio Biotechnology has higher earnings, but lower revenue than TriSalus Life Sciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	127.64	$6.40M	N/A	N/A
TriSalus Life Sciences	$45.15M	6.59	-$39.23M	-$1.30	N/A

Anbio Biotechnology has a beta of 5.4, suggesting that its share price is 440% more volatile than the broader market. Comparatively, TriSalus Life Sciences has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market.

Summary

Anbio Biotechnology and TriSalus Life Sciences tied by winning 6 of the 12 factors compared between the two stocks.

Get TriSalus Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TLSI vs. The Competition

Export

Metric	TriSalus Life Sciences	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$297.41M	$5.84B	$7.20B	$12.90B
Dividend Yield	N/A	1.75%	2.54%	11.28%
P/E Ratio	-3.72	25.92	273.16	25.45
Price / Sales	6.59	68.01	605.00	76.62
Price / Cash	N/A	33.03	76.74	53.00
Price / Book	43.91	6.18	12.98	6.14
Net Income	-$39.23M	$149.01M	$3.48B	$348.86M
7 Day Performance	-8.35%	-0.24%	0.13%	-0.80%
1 Month Performance	5.92%	6.18%	7.08%	4.13%
1 Year Performance	-7.47%	6.30%	24.67%	15.17%

TriSalus Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TLSI TriSalus Life Sciences	1.2345 of 5 stars	$4.83 -2.0%	$7.50 +55.3%	-7.5%	$297.41M	$45.15M	N/A	106	Positive News
DRTS Alpha Tau Medical	1.5261 of 5 stars	$14.38 +0.8%	$12.80 -11.0%	+328.1%	$1.30B	N/A	N/A	80
PRCT PROCEPT BioRobotics	3.6403 of 5 stars	$21.88 +2.6%	$28.00 +28.0%	-48.1%	$1.25B	$337.34M	N/A	430	Trending News
STAA STAAR Surgical	3.8728 of 5 stars	$25.12 +1.9%	$28.40 +13.1%	-19.2%	$1.25B	$239.44M	359.11	1,211
BVS Bioventus	4.5135 of 5 stars	$14.59 +2.0%	$16.80 +15.1%	+87.0%	$1.23B	$568.09M	18.92	1,200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TLSI) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TriSalus Life Sciences (TLSI) Competitors

TLSI vs. DRTS, PRCT, STAA, BVS, and NNNN

How does TriSalus Life Sciences compare to Alpha Tau Medical?

Summary

How does TriSalus Life Sciences compare to PROCEPT BioRobotics?

Summary

How does TriSalus Life Sciences compare to STAAR Surgical?

Summary

How does TriSalus Life Sciences compare to Bioventus?

Summary

How does TriSalus Life Sciences compare to Anbio Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSI vs. The Competition

TriSalus Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TriSalus Life Sciences (TLSI) Competitors

TLSI vs. DRTS, PRCT, STAA, BVS, and NNNN

How does TriSalus Life Sciences compare to Alpha Tau Medical?

Is TLSI or DRTS more profitable?

Do analysts recommend TLSI or DRTS?

Which has stronger earnings and valuation, TLSI or DRTS?

Does the media refer more to TLSI or DRTS?

Do insiders and institutionals believe in TLSI or DRTS?

Which has more risk & volatility, TLSI or DRTS?

Summary

How does TriSalus Life Sciences compare to PROCEPT BioRobotics?

Which has stronger valuation & earnings, TLSI or PRCT?

Is TLSI or PRCT more profitable?

Does the media favor TLSI or PRCT?

Do analysts rate TLSI or PRCT?

Do insiders & institutionals hold more shares of TLSI or PRCT?

Which has more risk & volatility, TLSI or PRCT?

Summary

How does TriSalus Life Sciences compare to STAAR Surgical?

Is STAA or TLSI more profitable?

Do insiders and institutionals hold more shares of STAA or TLSI?

Which has more volatility & risk, STAA or TLSI?

Do analysts recommend STAA or TLSI?

Which has better valuation and earnings, STAA or TLSI?

Does the media favor STAA or TLSI?

Summary

How does TriSalus Life Sciences compare to Bioventus?

Do analysts recommend TLSI or BVS?

Which has better earnings and valuation, TLSI or BVS?

Is TLSI or BVS more profitable?

Do institutionals & insiders hold more shares of TLSI or BVS?

Does the media refer more to TLSI or BVS?

Which has more risk and volatility, TLSI or BVS?

Summary

How does TriSalus Life Sciences compare to Anbio Biotechnology?

Do analysts prefer NNNN or TLSI?

Is NNNN or TLSI more profitable?

Does the media favor NNNN or TLSI?

Do insiders & institutionals have more ownership in NNNN or TLSI?

Which has stronger valuation & earnings, NNNN or TLSI?

Which has more risk and volatility, NNNN or TLSI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSI vs. The Competition

TriSalus Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools